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Vitamin D deficiency seems to predict the unsuccessful achievement of sustained viral
response (SVR) after antiviral treatment in hepatitis C virus (HCV) difficult-to-treat geno-
types. Vitamin D binding protein (GC) gene polymorphisms are known to influence vita-
min D levels. This study was performed to assess whether the interaction between basal
circulating vitamin D and the GC polymorphism plays a role in influencing the rate of
antiviral responses in patients affected by chronic hepatitis C. In all, 206 HCV patients
treated with a combination therapy of pegylated (PEG)-interferon plus ribavirin were ret-
rospectively evaluated. GC rs7041 G>T, GC rs4588 C>A, and IL-28B rs12979860 C>T
polymorphisms were genotyped. Frequencies of GC rs7041 G>T and rs4588 C>A poly-
morphisms were: G/G 5 64 (31.1%), G/T 5 100 (48.5%), T/T 5 42 (20.4%) and C/C 5
108 (52.4%), C/A5 84 (40.8%), A/A5 14 (6.8%). Patients were divided into those carry-
ing 3 major alleles (wildtype [WT]1: G-C/G-C, G-C/T-C, G-C/G-A, N 5 100) and the
remaining (WT2: G-C/T-A, T-A/T-C, T-A/T-A, T-C/T-C, N 5 106). Four groups were
identified: vitamin D 20 ng/mL and WT2, vitamin D 20 and WT1, vitamin D >20
and WT2, vitamin D >20 and WT1. In difficult-to-treat HCV genotypes the proportion
of patients achieving SVR significantly increased with a linear trend from the first to the
last group: 6/25 (24.0%), 9/24 (37.5%), 12/29 (41.4%), 19/29 (65.5%) (P 5 0.003). At
multivariate analysis, having basal vitamin D >20 ng/mL plus the carriage of GC WT1
was found to be an independent predictor of SVR (odds ratio 4.52, P 5 0.015). Conclu-
sion: In difficult-to-treat HCV genotypes, simultaneous pretreatment normal serum vita-
min D levels and the carriage of GC-globulin WT isoform strongly predicts the
achievement of SVR after PEG-interferon plus ribavirin antiviral therapy. (HEPATOLOGY
2012;56:1641-1650)
N
ew direct hepatitis C virus (HCV) protease
inhibitors (boceprevir and telaprevir) have
recently been introduced to be used in
combination with pegylated (PEG)-interferon and
ribavirin in the treatment of chronic hepatitis C.1,2
Triple antiviral therapy was associated with a signifi-
cant increase in sustained viral response (SVR) in
patients infected by HCV genotype 1. Nevertheless,
the need of interferon sensitiveness, the frequent low
tolerability, and the occurrence of multiple drug-to-
drug interactions will probably limit the use of these
molecules to selected populations.3 Therefore, afford-
able pretreatment predictors of SVR to standard
therapy will be useful to select naı¨ve patients in
whom side effects and costs of triple therapy could
be avoided without reducing the rate of SVR
achievement.
Several predictors of successful treatment of chronic
hepatitis C have been identified.4,5 Factors related to
the virus appear to be carefully characterized: infection
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by HCV genotypes 2-3 confers a much greater possi-
bility of a successful treatment than infection by geno-
types 1 and 4; other predictors are basal HCV viral
load and HCV genetic variability. Host predictors
are classifiable into genetic and nongenetic. Among
the latter, a higher degree of liver inflammation and
fibrosis and lower serum cholesterol values appear
to have a major role.4,6 Among the former, the
major genetic determinant of HCV clearance has been
identified in interleukin 28B (IL-28B) polymor-
phisms.7,8 Possessing the IL-28B rs12979860 C/C ge-
notype confers a greater advantage for HCV clearance
with standard therapy than the carriage of one or two
T alleles.7
Serum vitamin D concentration has been very
recently proposed as a novel predictor of HCV clear-
ance. In patients with genotype 1 chronic hepatitis
C, under standard PEG-interferon plus ribavirin
treatment, basal serum 25-hydroxylated vitamin D
concentration was found to be an independent pre-
dictor of viral clearance.9 Moreover, normal basal
vitamin D values were associated with a better antivi-
ral response to therapy than the presence of vitamin
D deficiency in patients with the same IL-28B geno-
type.10 Finally, vitamin D supplementation was asso-
ciated with an increased rate of SVR in patients with
HCV genotype 1 chronic hepatitis.11 Based on sev-
eral recent reports,12 vitamin D appears to possess
important immune-modulator effects that may
explain these observations.
Multiple factors are implicated in regulating vitamin
D levels and activity.13 GC-globulin is the main serum
vitamin D binding protein; it is polymorphic and
characterized in Caucasian populations by a great vari-
ability at two loci (rs7041 and rs4588). The carriage
of the minor alleles has been associated with lower cir-
culating vitamin D levels.14 The influence of these
polymorphisms on vitamin D levels in patients with
chronic hepatitis C and on the rate of antiviral
response to standard therapy for this infection has
never been investigated.
This study was performed to assess whether the
interaction between basal circulating vitamin D and
the polymorphism of its transporter (vitamin D axis)
plays a role in influencing the rate of antiviral
responses in patients affected by chronic hepatitis C.
Patients and Methods
Patients. The study population included a total of
206 consecutive, treatment-naı¨ve Caucasian hepatitis C
patients who were retrospectively evaluated. All the
patients received antiviral treatment at one of three
academic centers in northern Italy (the Medical Liver
Transplantation Unit of the University of Udine [N ¼
71, 34.5%], the Department of Gastroenterology of
the University of Verona [N ¼ 88, 42.7%], and the
Department of Clinical and Experimental Medicine,
University of Piemonte Orientale in Novara [(N ¼ 47,
22.8%]) from September 2005 to October 2009.
Chronic hepatitis C infection was defined by the pres-
ence of antihepatitis C virus antibodies, serum HCV
RNA positivity, and the persistent elevation of alanine
aminotransferase (ALT) for at least 6 months. In addi-
tion, 142 patients had had a liver biopsy performed
within the 6 months preceding the start of antiviral
therapy. Exclusion criteria were: decompensated liver
cirrhosis (Child-Pugh score >6), the presence of hepa-
tocellular carcinoma (HCC), HIV coinfection, HBV
coinfection, autoimmune liver disease, genetic liver dis-
ease (i.e., Wilson’s disease, hemochromatosis), concom-
itant use of drugs known to affect serum vitamin D
concentration, and active intravenous drug use. The
main clinical and demographic characteristics of the
studied population are reported in Table 1. The study
was conducted according to the principles of the Dec-
laration of Helsinki and approved by the hospital
Institutional Review Board and Ethical Committee. All
the patients signed a written informed consent to par-
ticipate into the study. The following variables were
recorded prior to treatment: age, sex, body weight,
height and body mass index (BMI), calculated on the
basis of body weight in kilograms and height in
meters. Alcohol intake was evaluated by a question-
naire and quantified in grams per day. An overnight
fasting blood sample was drawn to determine the base-
line blood tests, including HCV RNA quantification,
using real-time polymerase chain reaction (PCR) (Taq-
Man, Roche, Basel, Switzerland), and HCV genotype,
detected using the InnoLipa genotyping kit (Innoge-
netics, Zwijndrecht, Belgium). In all, 119 healthy
blood donors were used as controls. They were 73
males (61.3%) with a median age of 50 years (range
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25-65) and with a median BMI of 24 (range 18-33)
kg/m2. No significant difference was observed between
patients and controls in gender (P ¼ 0.084), age (P ¼
0.944), or BMI (P ¼ 0.112).
Vitamin D Assay. A pretreatment blood sample for
the 206 patients and a standard 8 hours fasting blood
sample for the 119 controls was collected, separated,
and stored at 80C until use. To quantify 25-OH
vitamin D serum levels the DiaSorin 25-OH vitamin
D chemoluminescent immunoassay on a Liaison auto-
matic analyzer (DiaSorin, Stillwater, MN) was used.
Molecular Biology. Genotyping for the IL-28B
rs12979860 C/T, for GC rs7041 T/G (Asp432Glu),
and for GC rs4588 C/A (Thr436Lys) polymorphisms
was performed by PCR-based restriction fragment
length polymorphism assay. Genomic DNA was
extracted from whole blood samples by means of the
QIAamp DNA blood mini kit (Qiagen, Milan, Italy)
according to the manufacturer’s instructions. For IL-
28B rs12979860 C/T a 145-basepair (bp) product was
obtained with the forward primer 50-GCCTGTCGT
GTACTGAACCA-30 and the reverse primer 50-
AGGCTCAGGGTCAATCACAG-30. For GC rs7041
T/G and GC rs4588 C/A polymorphisms a 125 bp
amplicon was obtained with the 50-TGGTTTTTCA-
GACTGGCAGA-30 forward and 50-GGAGGTGAG
TTTATGGAACAGC-30 reverse primers. All PCR
amplifications were carried out in a total volume of
10 lL. Samples containing 10 ng of genomic DNA
were subjected to 40 cycles of denaturation (95C for
30 sec), annealing (60C for 30 sec), and elongation
(72C for 30 sec) using a Techne TC-5000 thermal
cycler. In a total volume of 20 lL, amplified DNA
(10 lL) was digested overnight with 2 units of restric-
tion endonucleases using the buffers and temperatures
recommended by the manufacturer. Hpy166II restric-
tion endonuclease was used for IL-28B rs12979860 C/
T, HaeIII for GC rs 7041 T/G, and BtgI for GC
rs4588 C/A polymorphisms (all endonucleases from
New England Biolabs, Hitchin, UK). The restricted
fragments were 135 þ10 bp for the C allele and
105þ30þ10 bp for the T allele of IL-28B
rs12979860, 125 bp for the T allele and 89þ36 for
the G allele of GC rs7041, 125 bp for the A allele
and 71þ54 bp for the C allele of GC rs4588. The
fragments were resolved by electrophoresis on a 3.5%
agarose gel after staining with ethidium bromide. Hap-
lotype reconstruction from patients genotypes and
inferred phased diplotype calculation was performed
by means of the ARLEQUIN integrated software
package for population genetics. On the basis of the
diplotypes obtained and taking into account the num-
ber of major alleles present in the two loci studied,
patients were divided into two groups: WTþ
accounted for by those carrying three or four major al-
leles (G-C/G-C, G-C/T-C, G-C/G-A, N ¼ 100) and
WT accounted for by the remaining patients (G-C/
T-A, T-A/T-C, T-A/T-A, T-C/T-C, N ¼ 106). This
categorization was more capable of discriminating
patients with low or normal vitamin D values.
Histology. As mentioned above, 142 out of 206
patients (68.9%) underwent a liver biopsy before start-
ing therapy. Grade and stage were scored according to
the Ishak system.15
Antiviral Therapy Schedule and Outcomes. All
patients were treated with a combination therapy of
PEG-interferon plus ribavirin. In all, 145 patients
(70.4%) received pegylated interferon a-2b (Peg-Intron,
Schering-Plough) at a dosage of 1.5 lg/kg per week,
and 61 patients (29.6%) received pegylated interferon a-
2a (Pegasys, Roche), at a dosage of 180 lg per week. In
patients infected by HCV genotypes 1, 4, and 5, riba-
virin (either Rebetol, Schering-Plough, or Copegus,
Roche) was administered according to body weight
(1,000 mg/d for patients weighing <75 kg, 1200 mg/d
for 75 kg); in the case of infection by genotypes 2 and
3, a flat ribavirin dose of 800 mg/d was used. The dura-
tion of therapy was 48 weeks for genotypes 1, 4, and 5
and 24 weeks for genotypes 2 and 3. The definitions of
rapid viral response (RVR), complete early viral response
(cEVR), end of treatment viral response (EOT), SVR,
relapsers and nonresponders were made according to the
American Association for the Study of Liver Diseases
(AASLD) accepted guidelines.16
Table 1. Characteristics of the Studied Population at
Baseline (N5206)
Age, years 48 (17-77)
Male gender 106 (51.5%)
Body mass index kg/m2 24 (16-39)
HCV genotypes 1 92 (44.7%)
2 61 (29.6%)
3 38 (18.4%)
4-5 15 (7.3%)
HCV RNA (x 103 IU/mL) 700 (3.38-13000)
Cholesterol mg/dL 170 (72-327)
ALT IU/mL 68 (12-428)
cGT IU/mL 38 (6-875)
HOMA 2.0 (0.2-13.3)
Use of PEG-interferon a-2b 145 (70.4%)
Grading pretreatment* 2 (0-9)
Staging pretreatment* 2 (0-6)
Alcohol consumption g/day 0 (0-50)
Continuous variables are presented as median (range), while categorical vari-
ables are presented as frequencies (%).
ALT, alanine aminotransferase; cGT, gamma-glutamyl transpeptidase; HOMA,
homeostasis model assessment.
*Available in 142 patients.
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Statistical Analysis. Statistical analysis of the data
was performed using the BMDP dynamic statistical
software package 7.0 (Statistical Solutions, Cork, Ire-
land). Continuous variables are presented as median
(range) and categorical variables as frequencies (%).
The associations between categorical variables were
evaluated using the Pearson chi-squared test and, when
appropriate, the chi-squared test for linear trend. The
chi-squared G test ‘‘Goodness of Fit’’ was employed to
verify whether the proportions of the genetic polymor-
phisms were distributed in accordance with the Hardy-
Weinberg equation. Stepwise logistic regression analysis
with a forward approach was performed to identify in-
dependent predictors of SVR and nonresponse.
Results
Viral Response. RVR was achieved by 103 patients
(50.0%), cEVR by 150 (72.8%), EOT by 157
(76.2%), and SVR by 131 (63.6%) patients. The asso-
ciation between the achievement of SVR and the main
clinical and demographic variables known to influence
HCV viral clearance is reported in Table 2. In all
patients, univariate analysis showed that the SVR rate
was greatly influenced by viral genotype, IL-28B
rs12979860 C/T polymorphism, baseline serum cho-
lesterol, and gamma-glutamyltranspeptidase (cGT) lev-
els. In difficult-to-treat genotypes, besides the promi-
nent role exerted by IL-28B rs12979860 C/T
polymorphism, the rate of SVR was also strongly asso-
ciated with baseline serum HCV RNA and cholesterol
levels.
25-OH Vitamin D Levels. The median value of
circulating vitamin D was 20.7 (range 2.1-59.6) ng/
mL. In all, 111 (53.9%) patients had normal (>20
ng/mL) 25-OH vitamin D serum levels, whereas the
remaining 95 (46.1%) patients had vitamin D defi-
ciency (20 ng/mL). Control subjects had a median
vitamin D serum value of 28.4 (range 9.5-54.8) ng/
mL. Low vitamin D levels (20 ng/mL) were detected
in 95/206 patients with chronic hepatitis C and in 17/
119 control subjects (P < 0.0001). Very low vitamin
D levels (10 ng/mL) were detected in 32/206
patients with chronic hepatitis C and in 1/119 control
subjects (P < 0.0001).
GC-Globulin Polymorphisms. In patients with
chronic hepatitis C the following genotype frequencies
were detected: rs7041 G>T polymorphism G/G ¼ 64
(31.1%), G/T ¼ 100 (48.5%), T/T ¼ 42 (20.4%);
rs4588 C>A polymorphism C/C ¼ 108 (52.4%), C/
A ¼ 84 (40.8%), A/A ¼ 14 (6.8%). The correspond-
ing allele frequencies were: rs7041 G>T polymor-
phism G ¼ 0.553 and T ¼ 0.447; rs4588 C>A poly-
morphism C ¼ 0.728 and A ¼ 0.272. The genotype
frequencies for both loci were not found to differ from
what was expected from the Hardy-Weinberg equilib-
rium equation (P > 0.5 for both). The frequencies in
controls were: rs7041 G>T polymorphism G/G ¼ 40
Table 2. Sustained Viral Response in Chronic HCV-Infected Patients Treated With PEG-Interferon and Ribavirin in
Relationship to Baseline Demographic and Clinical Predictors
All Genotypes Genotypes 1/4-5
SVRþ SVR- SVRþ SVR-
N¼131 N¼75 P N¼46 N¼61 P
Age >50 years 58 32 0.823 14 24 0.340
Male gender 66 40 0.683 26 33 0.803
Body mass index >25 47 33 0.250 14 24 0.340
HOMA index <2.0 69 36 0.514 25 30 0.586
2.0–4.0 36 22 0.514 14 20 0.586
>4.0 26 17 7 11
Cholesterol 200 mg/dL 95 68 0.002 35 56 0.024
ALT >60 IU/mL 74 45 0.623 24 35 0.592
cGT >90 IU/mL 15 24 <0.001 7 20 0.038
HCV RNA >600.000 IU/mL 72 47 0.281 19 39 0.020
HCV genotype 1-4-5 46 61 <0.001 — — —
Use of PEG-interferon a-2b 88 57 0.182 26 46 0.039
Grading pretreatment >4* 17 12 0.492 4 9 0.201
Staging pretreatment >2* 35 26 0.148 16 22 0.411
Cumulative dose of IFN and RBV <80% 18 20 0.021 8 17 0.205
Alcohol consumption >20 g/day 16 8 0.739 6 7 0.806
IL-28B rs12979860 C/C 60 16 <0.001 24 8 <0.001
Data are presented for all and difficult to treat HCV genotypes. The statistical analysis was performed by means of Pearson chi-square test or chi-square test for
linear trend when appropriate.
SVR, sustained viral response, HOMA, homeostasis model assessment, ALT, alanine aminotransferase, cGT, gamma-glutamyl transpeptidase, IFN, interferon a.
*Available in 142 patients.
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(33.6%), G/T ¼ 65 (54.6%), T/T ¼ 14 (11.8%);
rs4588 C>A polymorphism C/C ¼ 59 (49.6%), C/A
¼ 57 (47.9%), A/A ¼ 3 (2.5%). The corresponding
allele frequencies were: rs7041 G>T polymorphism G
¼ 0.61 and T ¼ 0.39; rs4588 C>A polymorphism C
¼ 0.74 and A ¼ 0.26. Adopting the dominant model
for the major allele, patients were found to carry the
minor allele of both loci more frequently than con-
trols, although with a low level of significance (rs7041:
42/206 versus 14/119, P ¼ 0.047; rs4588: 14/206 ver-
sus 3/119, P ¼ 0.095). Haplotype frequencies in
patients were: G-C ¼ 55.1%, T-A ¼ 26.9%, T-C ¼
17.7% and G-A ¼ 0.3%. Diplotype frequencies were:
G-C/G-C ¼ 63 (30.5%), G-C/T-A ¼ 64 (31.1%), G-
C/T-C ¼ 36 (17.5%), T-A/T-C ¼ 19 (9.2%), T-A/T-
A ¼ 14 (6.8%), T-C/T-C ¼ 9 (4.4%), G-C/G-A ¼ 1
(0.5%). Table 3 illustrates the associations between
clinical and demographic parameters and GC-globulin
diplotypes. The carriage of the WTþ diplotype was
associated in all patients with higher vitamin D levels
and lower cGT serum values. The fact was confirmed
in patients infected by HCV difficult-to-treat viral ge-
notypes (Table 3).
GC-Globulin Polymorphisms, Vitamin D: Rela-
tionship With SVR and Nonresponse. Table 4 illus-
trates the rates of RVR, cEVR, EOT, and SVR as well
as of nonresponse to antiviral treatment in relationship
with the presence of normal vitamin D levels and with
the carriage of the WTþ diplotype. A normal vitamin
D value was mainly predictive of response in the initial
steps of the treatment, whereas carrying the WTþ dip-
lotype was important in determining later viral end-
points of the therapy. Interestingly, the carriage of the
WT diplotype was predictive of nonresponse to anti-
viral treatment. Combining vitamin D serum basal lev-
els and GC-globulin polymorphism, four groups were
identified: vitamin D 20 ng/mL and WT (N ¼
51), vitamin D 20 ng/mL and WTþ (N ¼ 44),
vitamin D >20 ng/mL and WT (N ¼ 55), vitamin
D >20 ng/mL and WTþ (N ¼ 56). A significant lin-
ear trend was observed in the proportion of patients
achieving SVR from the first to the last group: 29/51
(56.9%), 26/44 (59.1%), 33/55 (60.0%), 43/56
(76.8%, P ¼ 0.038). An even higher linear stratifica-
tion was detected in difficult-to-treat HCV genotypes:
6/25 (24.0%), 9/24 (37.5%), 12/29 (41.4%), 19/29
(65.5%, P ¼ 0.003) (Fig. 1A).
GC-Globulin, Vitamin D, and IL-28B Polymor-
phisms: Relationship With SVR and Nonresponse. In
patients carrying the IL-28B C/C genotype the rate of
SVR achievement was not influenced by GC-globulin
diplotypes. On the contrary, in patients carrying at
least one IL-28B T allele, WTþ had higher rates of
SVR in comparison to WT. Thus, combining IL-
28B and GC-globulin polymorphisms, SVR was found
to increase starting from T/* plus WT (33/72,
45.8%), to T/* plus WTþ (38/58, 65.5%), to C/C
plus WTþ/ (60/76, 78.9%) (P < 0.0001, Fig. 1B).
Table 3. Association Between GC-Globulin Diplotypes (WT1/-) and Demographic and Clinical Variables in Chronic HCV-
Infected Patients Treated With PEG-Interferon and Ribavirin
All Genotypes Genotypes 1/4-5
WTþ WT- WTþ WT-
N¼100 N¼106 P N¼53 N¼54 P
Age >50 years 44 46 0.930 19 19 0.943
Male gender 57 49 0.122 30 29 0.763
Body mass index >25 34 46 0.167 15 23 0.123
HOMA index <2.0 56 49 0.225 33 22
2.0–4.0 25 33 0.225 14 20 0.025
>4.0 19 24 6 12
Cholesterol 200 mg/dL 80 83 0.764 46 45 0.616
ALT >60 IU/mL 50 69 0.028 24 35 0.042
cGT >90 IU/mL 11 28 0.005 7 20 0.005
HCV RNA >600.000 IU/mL 60 59 0.529 28 30 0.777
HCV genotype 1-4-5 53 54 0.768 — — —
25-OH vitamin D ng/mL 10 10 22 5 11
>10–40 79 78 0.017 40 42 0.009
>40 11 6 8 1
Grading pretreatment >4* 13 16 0.590 7 6 0.660
Staging pretreatment >2* 27 34 0.298 17 21 0.562
IL-28B rs12979860 C/C 42 34 0.140 19 13 0.184
The statistical analysis was performed by means of Pearson chi-square test or chi-square test for linear trend when appropriate.
GC-globulin diplotype WTþ, carriage of at least three major alleles (G for the rs7041 and C for the rs4588), HOMA, homeostasis model assessment, ALT, ala-
nine aminotransferase, cGT, gamma-glutamyl transpeptidase, IL-28B, interleukin 28B.
*Available in 142 patients.
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The same occurred in difficult-to-treat HCV geno-
types: T/* plus WT (8/41, 17.4%), T/* plus WTþ
(14/34, 30.4%), C/C plus WTþ/ (24/32, 52.2%)
(P < 0.0001, Fig. 1B). A strong stratification among
groups was obtained simultaneously evaluating basal
vitamin D levels and GC-globulin polymorphisms in
relationship to IL-28B genotypes. SVR was attained in
14/35 (40.0%) IL-28B T/* genotypes and vitamin D
20 ng/mL and WT, in 35/64 (54.7%) IL-28B T/*
genotypes and either vitamin D levels 20 ng/mL or
GC-globulin WT diplotype, in 22/31 (71.0%) IL-
28B T/* genotypes and vitamin D levels >20 ng/mL
and GC-globulin WTþ diplotype, in 39/51 (76.5%)
IL-28B rs12979860 C/C genotype and one or both
vitamin D levels 20 ng/mL and GC-globulin WT
diplotype, in 21/25 (84.0%) IL-28B rs12979860 C/C
genotype and vitamin D levels >20 ng/mL and GC-
globulin WTþ diplotype (P < 0.0001). An even
Table 4. Rates of Rapid, Complete Early, End of Treatment, Sustained Viral Response, Nonresponders, Relapsers, and
Dropouts in Relationship With Normal Vitamin D Values and With GC-Globulin WT1 Diplotype
All Genotypes Genotypes 1/4-5
N¼206 N¼107
Vit. D >20 WTþ Vit. D >20 WTþ
N N¼111 P N¼100 P N N¼58 P N¼53 P
Rapid viral response 103 65 (58.6%) 0.008 51 (51.0%) 0.780 29 24 (41.4%) <0.001 15 (28.3%) 0.782
Complete early viral response 150 89 (80.2%) 0.010 80 (80.0%) 0.024 56 38 (65.5%) 0.003 33 (62.3%) 0.042
End of treatment viral response 157 91 (82.0%) 0.036 85 (85.0%) 0.004 65 40 (69.0%) 0.058 40 (75.5%) 0.002
Sustained viral response 131 76 (68.5%) 0.116 69 (69.0%) 0.117 46 31 (53.4%) 0.017 28 (52.8%) 0.042
Nonresponders 32 14 (12.6%) 0.211 8 (8.0%) 0.004 32 14 (24.1%) 0.156 8 (15.1%) <0.001
Relapsers 26 15 (13.5%) 0.677 16 (16.0%) 0.156 19 9 (15.5%) 0.510 12 (22.6%) 0.190
Dropout 17 5 (4.5%) 0.035 7 (7.0%) 0.526 11 4 (6.9%) 0.210 4 (7.5%) 0.356
Data are presented considering all patients and difficult to treat HCV genotypes.
Vit. D >20, basal Vitamin D serum levels >20 ng/mL. WTþ, carriage of at least three major alleles (G for the rs7041 and C for the rs4588) for the GC-
globulin.
Fig. 1. (A) Rates of SVR in relationship with basal vitamin D serum levels (/>20 ng/mL) and GC-globulin rs7041 G>T and rs4588 C>A
polymorphisms (WTþ/). Patients were divided into four groups: vitamin D levels >20 ng/mL and WTþ diplotype, vitamin D levels >20 ng/
mL and WT diplotype, vitamin D levels 20 ng/mL and WTþ diplotype, vitamin D levels 20 ng/mL and WT diplotype. (B) Rates of SVR in
relationship with the simultaneous assessment of IL-28B rs12979860 C/T polymorphism and GC-globulin rs7041 G>T and rs4588 C>A poly-
morphisms (WTþ/). Patients were divided into three groups: IL-28B rs12979860 C/C genotype irrespective of GC-globulin WT diplotype, IL-
28B rs12979860 C/T or T/T genotypes and GC-globulin WTþ diplotype, IL-28B rs12979860 C/T or T/T genotypes and GC-globulin WT diplo-
type. Results are presented in all HCV genotypes and separately in genotypes 1-4-5 and 2-3. The statistical analysis was performed by means
of chi-square test for linear trend. WTþ diplotype: carriage of 3 major alleles (G-C/G-C, G-C/T-C, G-C/G-A), WT diplotype: the remaining
patients (G-C/T-A, T-A/T-C, T-A/T-A, T-C/T-C).
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higher linear stratification was observed in difficult-to-
treat HCV genotypes: 3/21 (14.3%), 11/37 (29.7%),
8/17 (47.1%), 13/20 (65.0%), 11/12 (91.7%) (P <
0.0001, Fig. 2).
Multivariate Analysis in the Prediction of SVR
and Nonresponse. Table 5 illustrates the main demo-
graphic and clinical variables as well as IL-28B poly-
morphism in the prediction of viral nonresponse to
interferon and ribavirin treatment in difficult-to-treat
1/4-5 HCV genotypes. Stepwise logistic regression
analysis was performed in order to verify whether the
interaction between GC-globulin polymorphisms and
serum vitamin D could be considered an independent
predictor of SVR. Variables included were those pre-
sented in Table 3 plus GC-globulin polymorphism
diplotypes and their interaction with serum vitamin D.
For the purposes of the analysis two groups were iden-
tified: patients with serum vitamin D >20 ng/mL and
WTþ (N ¼ 56) and the remaining patients (N ¼
150). Besides the major role played by HCV geno-
types and IL-28B polymorphism, the interaction
between serum vitamin D levels and GC-globulin dip-
lotypes was found to be a strong independent predic-
tor of SVR in HCV chronic infected patients treated
with interferon a and ribavirin (Table 6). In difficult-
to-treat HCV genotypes viral nonresponse was found
to be independently associated with the carriage of the
T allele of IL-28B polymorphism and with the carriage
of the GC-globulin WT diplotypes (Table 6).
Discussion
GC-globulin is a serum glycosylated a2-globulin
with a molecular weight of about 58 kDa. The amino
acid sequence is composed of 458 residues arranged in
three domains. Low serum levels have been detected in
critically ill patients with sepsis or organ dysfunction
and in the presence of more advanced liver fibrotic
stages.17 GC-globulin gene is localized on the long
arm of chromosome 4 and belongs to a cluster com-
posed of four genes including albumin, a-fetoprotein
and a-albumin/afamin. The marked homology in nu-
cleotides and amino acid sequences among these pro-
teins supports the hypothesis that these four genes
derive from a unique ancestral gene.18 All these four
Fig. 2. Rates of SVR in relationship with IL-28B rs12979860 C/T
polymorphism, vitamin D levels (/>20 ng/mL), and GC-globulin
rs7041 G>T and rs4588 C>A polymorphisms (WTþ/). Patients
were divided into five groups: IL-28B rs12979860 C/C genotype and
vitamin D levels >20 ng/mL and GC-globulin WTþ diplotype, IL-28B
rs12979860 C/C genotype and one or both vitamin D levels 20
ng/mL and GC-globulin WT diplotype, IL-28B rs12979860 C/T or T/
T genotypes and vitamin D levels >20 ng/mL and GC-globulin WTþ
diplotype, IL-28B rs12979860 C/T or T/T genotypes and either vita-
min D levels 20 ng/mL or GC-globulin WT diplotype, IL-28B
rs12979860 C/T or T/T genotypes and vitamin D levels 20 ng/mL
and GC-globulin WT diplotype. Results are presented in all HCV ge-
notypes and separately in genotypes 1-4-5 and 2-3. The statistical
analysis was performed by means of chi-square test for linear trend.
WTþ diplotype: carriage of 3 major alleles (G-C/G-C, G-C/T-C, G-C/
G-A), WT diplotype: the remaining patients (G-C/T-A, T-A/T-C, T-A/T-
A, T-C/T-C).
Table 5. Viral Nonresponse in Chronic HCV-Infected Patients
Treated with PEG-Interferon and Ribavirin in Relationship to
Baseline Demographic and Clinical Predictors
Genotypes 1/4-5
Nonresponse Response
N¼32 N¼75 P
Age >50 years 12 (37.5%) 26 (34.7%) 0.779
Male gender 15 (46.9%) 44 (58.7%) 0.262
Body mass index >25 12 (37.5%) 26 (34.7%) 0.779
HOMA index <2.0 14 (43.4%) 41 (54.7%)
2.0–4.0 11 (34.4%) 23 (30.7%) 0.252
>4.0 7 (21.9%) 11 (14.7%)
Cholesterol 200 mg/dL 29 (90.6%) 62 (82.7%) 0.291
ALT >60 IU/mL 19 (59.4%) 40 (53.3%) 0.565
cGT >90 IU/mL 15 (46.9%) 12 (16.0%) <0.001
HCV RNA >600.000 IU/mL 19 (59.4%) 39 (52.0%) 0.483
Use of PEG-interferon a-2b 23 (71.9%) 49 (65.3%) 0.509
Grading pretreatment >4* 3 (12.0%) 10 (16.7%) 0.586
Staging pretreatment >2* 12 (48.0%) 26 (43.3) 0.693
Cumulative dose of IFN and RBV <80% 7 (21.9%) 18 (24.0%) 0.812
Alcohol consumption >20 g/day 4 (12.5%) 9 (12.0%) 0.942
IL-28B rs12979860 C/C 2 (6.2%) 30 (40.0%) <0.001
Data are presented for 1/4-5 HCV genotypes; in easy to treat 2-3 HCV geno-
types no nonresponse was detected. The statistical analysis was performed by
means of Pearson chi-square test or chi-square test for linear trend when
appropriate.
HOMA, homeostasis model assessment, ALT, alanine aminotransferase, cGT,
gamma-glutamyl transpeptidase, IFN, interferon a.
*Available in 142 patients.
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genes are expressed almost exclusively in the liver. A
considerable GC-globulin polymorphism has been
demonstrated in humans and primates initially using
electrophoretic methods.19 Three predominant iso-
forms have been described, originating from the
genetic recombination of the two main polymorphic
loci: the rs7041 G>T and the rs4588 C>A transver-
sions. The isoform 1f encompasses the rs7041 T and
rs4588 C haplotype, the 1s the G-C haplotype, and
finally the isoform 2 encompasses the T-A haplotype.
In this study, as already reported in the literature
concerning Caucasian populations,20 the G allele of
the rs7041 G>T and the C allele of the rs4588 C>A
polymorphisms of GC-globulin gene were found to be
the major alleles. Taking particularly into account hap-
lotype frequencies, GC-1s was the more frequent form
found in comparison to GC-1f, whereas GC-2 was far
less frequent; in our series the very rare GC G-A hap-
lotype was present only in one patient. The primary
amino acid sequences of GC-1s and GC-1f isoforms
are identical, except for the 416 position where glu-
tamic acid is substituted by aspartic acid. On the other
hand, GC-1f and GC-2 differ by a single amino acid
modification in position 420 (threonine versus lysine).
These variations were associated with lower GC-globu-
lin circulating levels.21
Several studies have been performed to ascertain
whether GC-globulin polymorphisms influence serum
vitamin D levels.14 There is substantial agreement that
the carriage of the major alleles of GC rs7041 G>T
and rs4588 C>A polymorphisms, in particular the
GC-1s and GC-1f isoforms, is associated with higher
serum vitamin D. To assess the overall influence of the
two polymorphic loci of GC-globulin on vitamin D
levels, diplotype analysis was performed. Patients were
divided into two groups: the first (GC-globulin WTþ)
composed of those carrying 3 or 4 major alleles of
rs7041 G>T and rs4588 C>A polymorphic loci, the
second (GC-globulin WT) composed of the remain-
ing patients. A significant association was detected
between the carriage of WT diplotype and the pres-
ence of lower vitamin D values.14 Although patients
were found to carry the minor allele of both loci more
frequently than controls, no difference was observed in
diplotype frequencies between the two groups. On the
contrary, vitamin D values were found to be exceedingly
lower in patients with chronic hepatitis C in comparison
to matched control subjects, as reported.22 The degree
of fibrosis in chronic liver diseases has been found to be
a strong determinant of vitamin D deficiency, due to
the implication of liver function in vitamin D metabo-
lism.9 Nevertheless, no clear explanation exists about the
etiological role of HCV in determining, even in the
presence of modest liver fibrosis, a fall in vitamin D lev-
els. A direct implication of HCV in interfering in the
cellular pathways of vitamin D activation has been sup-
posed. Although whether vitamin D deficiency associates
or not with faster fibrosis progression in chronic hepati-
tis C is debated.23,24
In this study the rate of SVR in all patients was
found to be 63.6%; in agreement with that reported
in the literature, it was 43.0% in difficult-to-treat and
85.9% in easy-to-treat HCV genotypes.25 IL-28B
rs12979860 C/T polymorphism was confirmed to play
a pivotal role in predicting the rate of SVR,7 inde-
pendently of other well-known predictors, such as
HCV genotype, HCV viral load, and baseline serum
cholesterol. The novelty of this study resides in the
fact that for the first time vitamin D axis determinants
were found to greatly influence the rate of viral
Table 6. Summary of the Results of Stepwise Logistic Regression Analysis in the Prediction of Sustained
Viral Response in All HCV Genotypes
Sustained Viral Response Nonresponse
All HCV Genotypes HCV Genotypes 1/4-5 HCV Genotypes 1/4-5
OR 95% CI P OR 95% CI P OR 95% CI P
HCV genotypes 2-3 9.58 4.47-20.5 <0.001 — — — — — —
IL-28B C/C genotype 3.25 1.49-7.05 0.003 12.5 3.77-41.7 <0.001 0.090 0.018-0.452 <0.001
Vitamin D >20 ng/mL / WTþ 3.30 1.44-7.55 0.015 4.52 1.47-13.9 0.015 — — —
HCV RNA 600.000 I.U./mL 2.53 1.21-5.26 0.010 5.77 1.96-17.0 0.001 — — —
Serum cholesterol mg/dL 1.01 1.00-1.02 0.008 1.02 1.00-1.04 0.010 0.981 0.965-0.998 0.019
GC-globulin diplotypes WTþ — — — — — — 0.164 0.056-0.482 0.002
In difficult to treat 1/4-5 HCV genotypes results concerning both sustained viral response and no-response are reported. The variables included in the analysis
were those reported in table 2 (except for histology available in 142 patients), GC-globulin diplotypes (WT þ/-), serum vitamin D (/>20 ng/mL) and their inter-
action: vitamin D >20 ng/mL plus GC WTþ (N¼56) versus the remaining patients (N¼150).
OR, odds ratio, CI, confidence interval, IL-28B, interleukin 28B, GC-globulin diplotype WTþ, carriage of at least three major alleles (G for the rs7041 and C for
the rs4588) for the GC-globulin.
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clearance after interferon and ribavirin treatment in
patients with chronic HCV infection. Although serum
basal vitamin D deficiency seems to greatly affect the
initial processes leading to viral decline, genetic deter-
minants regulating vitamin D appear to possess a per-
sistent influence on vitamin D-related immunological
mechanisms associated with HCV clearance. Accord-
ingly, a strong association was found between the
interaction between vitamin D levels (/>20 ng/mL)
and GC-globulin diplotype carriage (WTþ/WT)
and HCV clearance in difficult-to-treat genotypes.
Patients possessing normal vitamin D levels and carry-
ing the WTþ diplotype achieved SVR in 65.5% of
the cases; at the opposite, those with vitamin D defi-
ciency and carrying the WT diplotype achieved SVR
only in 24.0% of the cases.
Although an extensive analysis has been previously
performed on predictors of SVR achievement in patients
with chronic hepatitis C, scarce data are present in the
literature on the prediction of nonresponse to antiviral
treatment.4 In the present study about one-third of
patients infected by difficult-to-treat HCV genotypes
were found to be nonresponders to interferon plus riba-
virin therapy. This result is similar to that previously
detected in a larger series.25 Carriage of the T allele of
IL-28B rs12979860 C/T polymorphism was confirmed
to be associated with nonresponse.26 Interestingly, in
this study, for the first time the carriage of the GC-glob-
ulin WT diplotype was strongly and independently
associated with the condition of nonresponder to antivi-
ral therapy. Thus, it may be postulated that the capacity
of induce a positive response to antiviral therapy in
chronic HCV infection could be influenced by the pres-
ence of an efficient vitamin D transport capacity in turn
conditioning a normal vitamin D bioavailability. In fact,
vitamin D has been suggested to possess an antiviral
effect in an in vitro infectious HCV production sys-
tem.27 Low vitamin D levels were associated in vivo
with a poor response to antiviral treatment for patients
affected by chronic hepatitis C.9,10,28
Besides its role as vitamin D transporter, GC-globu-
lin possesses a number of other functions implicated
in the modulation of the inflammatory response. First,
GC-globulin has the ability to bind actin released into
the circulation by necrotic cell destruction, thus pro-
tecting against disseminated intravascular coagula-
tion.29 Second, GC-globulin may be converted, fol-
lowing partial deglycosylation operated by enzymes
released by inflammatory cells, into the GC-macro-
phage activating factor (GC-MAF).30 Finally, GC-
globulin can transport lipids such as arachidonic acid
and endotoxin and can exert immunomodulatory func-
tion enhancing the chemotactic activity of the C5a.31
Altogether, these biological functions could imply a
vitamin D-independent role of GC-globulin polymor-
phisms in influencing the response to interferon in the
treatment of hepatitis C.
In patients infected by difficult-to-treat HCV geno-
types, may vitamin D axis assessment improve pretreat-
ment prediction of antiviral standard therapy outcome?
Looking at the probability of SVR achievement, one
might first of all demonstrate that GC-globulin evalua-
tion could improve the power of the major host genetic
predictor, IL-28B rs12979860 C/T polymorphism. In
effect, carriage of the IL-28B C/C genotype was con-
firmed to possess great strength in the prediction of a
positive outcome of therapy. Interestingly, in patients
carrying the less favorable IL-28B rs12979860 C/T and
T/T genotypes, carriage of the WTþ diplotype was
associated with a doubling chance of SVR in compari-
son to the carriage of WT GC-globulin diplotype
(41.2% versus 19.5%). Finally, GC-globulin polymor-
phisms evaluation appears to be interesting in the iden-
tification of true nonresponders to antiviral treatment
and therefore in predicting patients prone to have inter-
feron resistance. In this category of patients, interferon-
based antiviral treatment, although clinically indicated,
would be associated with a poor response rate not mod-
ifiable by adding the new direct antiviral agents.
This study has some limitations. First, it analyzed
only Caucasian subjects of northern Italy; thus, the
results could be replicated in other ethnicities carrying
different allelic frequencies for the GC-globulin rs7041
and rs4588 loci. Second, the design of the study is ret-
rospective. Third, only a baseline serum vitamin D
determination was available and analyzed; moreover, no
GC-globulin serum levels were tested because stored se-
rum was available only in a minority of patients.
In conclusion, genetic study of IL28B could be inte-
grated with the genetic study of GC-globulin polymor-
phisms to better identify pretreatment patients with a
higher probability to have interferon resistance, a con-
dition limiting the successful use of new direct antivi-
ral agents. In difficult-to-treat HCV genotypes, simul-
taneous pretreatment normal serum vitamin D levels
and carriage of the GC-globulin wildtype isoform
strongly predict the achievement of SVR after PEG-
interferon plus ribavirin antiviral therapy.
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